BioVie Inc. Discusses Clinical Progress of Bezisterim in Parkinson's, Alzheimer's, and Long COVID.

BioVie Inc. (BIVI) discussed the clinical progress of Bezisterim, a drug targeting inflammation in Parkinson's, Alzheimer's, and Long COVID. Patients treated with Bezisterim experienced reduced inflammation and associated insulin resistance, improved muscle control in Parkinson's, improved cognition and function in Alzheimer's, and lower levels of DNA methylation, which modulates biological aging. The drug modulates the production of TNF alpha and has shown promising results in clinical trials.